methyl (E)-3-(4'-cyanobiphenyl-4-yl)-acrylate | 918332-97-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl (E)-3-(4'-cyanobiphenyl-4-yl)-acrylate
• 英文别名: methyl 3-(4-cyanobiphenylyl)acrylate；methyl (E)-3-[4-(4-cyanophenyl)phenyl]prop-2-enoate
• CAS: 918332-97-5
• 化学式: C₁₇H₁₃NO₂
• 分子量: 263.296
• InChiKey: XQWZWXXRFXLADA-IZZDOVSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  O-(四氢-2H-吡喃-2-基)羟基胺 、 methyl (E)-3-(4'-cyanobiphenyl-4-yl)-acrylate 在 sodium hexamethyldisilazane 、 水 、 氯化铵 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 (E)-3-(4'-cyanobiphenyl-4-yl)-N-(tetrahydropyran-2-yloxy)-acrylamide
  参考文献：
  名称：

  WO2007/383

  摘要：

  公开号：
• 作为产物：
  描述：

  3-(4-溴苯基)-2-丙酸甲酯 、 4-氰基苯硼酸 在 四(三苯基膦)钯 sodium carbonate 作用下， 以 甲醇 、 水 、 甲苯 为溶剂， 反应 9.0h， 生成 methyl (E)-3-(4'-cyanobiphenyl-4-yl)-acrylate
  参考文献：
  名称：

  WO2007/383

  摘要：

  公开号：

文献信息

• LIQUID CRYSTAL DISPLAY ELEMENT
  申请人：DAI NIPPON PRINTING CO., LTD.

  公开号：EP1890187A1

  公开（公告）日：2008-02-20

  A main object of the present invention is to provide a liquid crystal display, using a ferroelectric liquid crystal exhibiting mono-stability, which makes it possible to control the direction of the spontaneous polarization of the ferroelectric liquid crystal. To achieve the object, the present invention provides a liquid crystal display comprising: a first alignment treatment substrate having a first substrate, a first electrode layer formed on the first substrate, and a first alignment layer formed on the first electrode layer; and a second alignment treatment substrate having a second substrate, a second electrode layer formed on the second substrate, a second alignment layer formed on the second electrode layer, and a reactive liquid crystal layer formed on the second alignment layer and obtained by fixing a reactive liquid crystal; in which the first alignment treatment substrate and the second alignment treatment substrate are provided to have the first alignment layer and the reactive liquid crystal layer facing each other; and in which a ferroelectric liquid crystal is held between the first alignment layer and the reactive liquid crystal layer; characterized in that the ferroelectric liquid crystal exhibits mono-stability; and further characterized in that, when a negative voltage is applied to the second electrode layer, the molecular direction of the ferroelectric liquid crystal is changed by about 2 times the tilt angle of the ferroelectric liquid crystal parallel to the surface of the first alignment treatment substrate.

  本发明的一个主要目的是提供一种液晶显示器，该显示器使用一种具有单稳 定性的铁电液晶，从而可以控制铁电液晶的自发极化方向。为实现上述目的，本发明提供了一种液晶显示器，包括第一对准处理基板，具有第一基板、形成在第一基板上的第一电极层以及形成在第一电极层上的第一对准层；以及 第二对准处理基板，具有第二基板、形成在第二基板上的第二电极层、形成在第二电极层上的第二对准层以及形成在第二对准层上并通过固定活性液晶而获得的活性液晶层；其中，第一对准处理基板和第二对准处理基板设置为使第一对准层和活性液晶层彼此面对；其中，在第一对准层和反应液晶层之间固定有铁电液晶；其特征在于，铁电液晶表现出单稳态；进一步特征在于，当在第二电极层上施加负电压时，铁电液晶的分子方向会发生改变，改变幅度约为铁电液晶平行于第一对准处理基板表面的倾斜角的 2 倍。
• LIQUID CRYSTAL DISPLAY DEVICE
  申请人：DAI NIPPON PRINTING CO., LTD.

  公开号：EP1710617B1

  公开（公告）日：2010-10-13
• Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors
  作者：Sabrina Dallavalle、Raffaella Cincinelli、Raffaella Nannei、Lucio Merlini、Gabriella Morini、Sergio Penco、Claudio Pisano、Loredana Vesci、Marcella Barbarino、Valentina Zuco

  DOI：10.1016/j.ejmech.2008.11.005

  日期：2009.5

  A series of hydroxamic acid-based histone deacetylase (HDAC) inhibitors were designed on the basis of a model of the HDAC2 binding site and synthesized. They are characterized by a cinnamic spacer, capped with a substituted phenyl group. Modifications of the spacer are also reported. In an in vitro assay with the isoenzyme HDAC2, a good correlation of the activity with the docking energy was found. In human ovarian carcinoma IGROV-1 cells, selected compounds produced significant acetylation of p53 and alpha-tubulin. Most compounds showed an antiproliferative activity comparable to that of SAHA. At equitoxic concentrations, the tested compounds were more effective than SAHA in inducing apoptotic cell death. Compounds selected for in vivo evaluation exhibited a significant antitumor activity on three tumor models at well tolerated doses, thus suggesting a good therapeutic index. (C) 2008 Elsevier Masson SAS. All rights reserved.
• WO2007/383
  申请人：——

  公开号：——

  公开（公告）日：——